Position statement: global neuraminidase inhibitor susceptibility network.
about
Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitorsNeuraminidase inhibitors for preventing and treating influenza in children (published trials only)Neuraminidase inhibitors for preventing and treating influenza in childrenNeuraminidase inhibitors for preventing and treating influenza in childrenNeuraminidase inhibitors for influenza B virus infection: efficacy and resistanceTreatment of influenza with neuraminidase inhibitors: virological implicationsInhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion proteinHuman-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza virusesMutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemicModel answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningDrug resistance in influenza A virus: the epidemiology and management.Oseltamivir in the management of influenza.Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08Deep Sequencing for Evaluation of Genetic Stability of Influenza A/California/07/2009 (H1N1) Vaccine VirusesRapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hostsAssessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A virusesNeuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virusThe 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.Surveillance for antiviral resistance.Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitorPhenotypic drug susceptibility assay for influenza virus neuraminidase inhibitorsNeuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitorsEvaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.T-705 (favipiravir) activity against lethal H5N1 influenza A virusesRapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host.Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Neuraminidase inhibitors for the treatment and prevention of influenza.Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza virusesEffect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virusZanamivir in the treatment of influenza.
P2860
Q22305941-D7C7E9BC-98DC-4160-A129-FD9C63371054Q24200222-EDFEB64A-9663-4AA6-9ABF-39E9213F83F7Q24203875-83379536-4A39-4EE4-A05E-3C3ADE486605Q24243136-9AD9195A-A3E4-42BC-9E4F-17D9AD8CF6FDQ27021579-FA97C372-C7CA-4789-B422-512EFBF4427AQ28344588-E60ACE3C-41AE-4D0E-9207-B2CF01E2803BQ28471835-245CAF27-CCEC-476E-AB49-7705C58BF794Q28472513-7DACE503-DDFF-4812-B810-C88846696F7EQ28477952-A4A645BD-D645-44CE-BD48-B816554ED4DEQ30230076-C7D2AEA7-39FE-4FB6-888F-3BA5585875F8Q30234600-BE4DD6FE-39F0-488C-A024-47FAECFADC41Q30351736-49165C56-32EA-4FC1-AB17-AB375E92FF6AQ30352557-A425BC9C-9031-43BB-AB47-84511FF2DAB0Q30364892-874844A7-D53C-49D7-B2CF-FA99C759620BQ30374740-4D72AD6E-C259-4BC5-B5D2-5E8A83A85F53Q30379542-B2877ACF-BC7E-4B81-BBA3-4A9896AA8C62Q30387332-803A5C81-11F2-41E8-94AC-AD6538519E83Q30390818-5F06E369-BCF4-48C4-A4C0-A6CA6B7A9CBBQ30393843-B6105B75-0BFC-4046-A37D-E8DA990E53A9Q30394067-3D1FF5B0-023A-43C0-956E-C839E0F1BEB4Q30400058-DF6025A4-B9E9-4EB1-850B-D33EE406009FQ30410229-9AD392B2-E0F5-48E0-9D7B-B049EBE784B0Q30425350-D7B01F87-E3C3-4DF8-A36C-2E2359846CDFQ30445738-85834530-B518-4FAF-970F-A780B3224337Q30448118-A20B9D15-941C-48A7-B9E3-B6309E847FA7Q30450742-1AFAD5CF-A56B-43CD-9DC0-F27BAE762E78Q30452889-3C8EB116-233D-4D7C-B50E-DBFE697078BFQ30452892-EE5BBF51-8489-4AA0-B1B6-BE7EC3B3EBE5Q30453005-52465D27-B4C5-4103-9AB2-610A074CD9A7Q33639979-0FBC6B78-EC4A-4712-842A-F58C8AEC3555Q33776525-A0A27058-5DE3-4AD8-99F8-0BB77B0ECBB6Q34046111-B1233F66-62B5-4D20-9D8C-00C0F187BC0BQ34077100-89E7F4BF-3F5E-4B8A-B5A5-2B89B238F998Q34405859-5A6BD709-8963-4755-852B-0B9230ECECAEQ34519220-84653A0A-5B9E-4575-91B1-911CB5D06158Q34706374-F8A59990-7B48-4130-8E11-96FA45DE036BQ34759825-73211A83-0B4E-4AAF-88DF-8C546F79674AQ35024169-14E2C932-4B67-4B75-A1A7-DE96A9D7DF47Q35076785-8EB2F23C-49FB-4C21-871F-14DABE78446EQ35124722-27466139-5071-46D8-B88A-584050F72EA4
P2860
Position statement: global neuraminidase inhibitor susceptibility network.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Position statement: global neuraminidase inhibitor susceptibility network.
@ast
Position statement: global neuraminidase inhibitor susceptibility network.
@en
Position statement: global neuraminidase inhibitor susceptibility network.
@nl
type
label
Position statement: global neuraminidase inhibitor susceptibility network.
@ast
Position statement: global neuraminidase inhibitor susceptibility network.
@en
Position statement: global neuraminidase inhibitor susceptibility network.
@nl
prefLabel
Position statement: global neuraminidase inhibitor susceptibility network.
@ast
Position statement: global neuraminidase inhibitor susceptibility network.
@en
Position statement: global neuraminidase inhibitor susceptibility network.
@nl
P2093
P1433
P1476
Position statement: global neuraminidase inhibitor susceptibility network.
@en
P2093
F G Hayden
Global Neuraminidase Inhibitor Susceptibility Network
P304
P356
10.1016/S0166-3542(01)00124-3
P577
2001-03-01T00:00:00Z